Module 9 Pre-Test Complex Cases in Buprenorphine Treatment, Part 2

PRE-TEST SURVEY

Please complete the following pre-test to help us assess your knowledge of the course material prior to completing this training session.

IMPORTANT!!
Once you complete the pre-test and FINISHED, you will be able to view your test results. After viewing your results, click DONE.

If you have difficulties completing this survey, please contact Amy Wales at amy.wales@miccsi.org.

Demographics

Question Title

* 1. Personal Information

First Name

Last Name

Credential

Question Title

* 2. Please choose your organization from the choices below:

Affinia Health Network-Lakeshore (Lakeshore Health Network)

Answer Health (WMPN/POWM)

Borgess Health/Ascension

Bronson Healthcare

Blue Cross Blue Shield of Michigan or Blue Care Network

CIPA

Covenant Healthcare

Genesys

Great Lakes Bay Health

Great Lakes PHO

Henry Ford Health System

Holland PHO

Huron Valley Physicians Association (HVPA)

IHA

Lakeland Care

McLaren Health

Mercy Health Physicians Partners-Grand Rapids

Munson Healthcare

Metro Health

Northern Physician Organization (NPO)

Priority Health

Spectrum Health

Thunder Bay Health Centers

University of Michigan

Upper Peninsula Health System

Wexford PHO

Other (please specify)

Question Title

* 3. Please list the name of your practice. If not applicable, type "N/A".

Question Title

* 4. Please choose your role in your practice:

Physician

Advanced practice provider (physician assistant, nurse practitioner, etc.)

Nurse care manager/care coordinator

Social worker care manager/behavioral health specialist

Pharmacist

Leadership

Other clinical (CMA, RMA, etc.)

Other non-clinical (support staff, etc.)

Other (please specify)

Pre-Training Confidence Assessment

Please use the following scale to answer questions 5 and 6.

1: Not confident at all
2: Slightly confident
3: Somewhat confident
4: Fairly confident
5: Completely confident

Question Title

* 5. On a scale of 1-5 please rate your confidence in managing substance use disorder.

Question Title

* 6. On a scale of 1-5 please rate your confidence in managing complex cases in buprenorphine treatment.

Pre-Training Knowledge Assessment

Question Title

* 7. Which of the following is/are advantages of using clonazepam once the decision is made to wean a patient off of benzodiazepine therapy?

Clonazepam has a longer half-life than alprazolam (Xanax).

Clonazepam has a shorter half-life than alprazolam (Xanax).

Clonazepam has lower reinforcement potential than alprazolam (Xanax).

Both A and C

Question Title

* 8. Which of the following is true?

It is not possible to tell, from a UDS, exactly how much of a substance a patient is taking and how often.

A UDS can tell you the exact amount of buprenorphine being ingested over a given period of time.

If a UDS shows an unexpected result, you should not proceed with treatment until you are absolutely confident the patient is telling you the truth about their drug use.

None of these are true.

Question Title

* 9. Which of the following is true regarding taper off of benzodiazepine use?

Withdrawal is minimal, even with chronic use.

A cold-turkey approach is the best option.

A slow and gradual taper is the best option.

If a patient is using benzodiazepines at baseline, they should always continue using while they’re on buprenorphine therapy.

Question Title

* 10. Which of the following is true?

Buprenorphine is contraindicated during pregnancy.

Naloxone is the preferred medication for opioid use disorder in pregnancy.

Buprenorphine is safe for use during pregnancy.

Pregnant patients should not use any medication to treat opioid use disorder until after they deliver.